



# MicroDoseTherapeutx

## Passion, Innovation and Excellence in Every Breath

Founded in 1998, MicroDose Therapeutx is a specialty pharmaceutical company successfully pioneering the creation of next-generation products utilizing its proprietary drug delivery technologies. In the pipeline, its Dry Powder Inhaler, PolyCap™ FDC capsule system, and Needlefree technologies promise to dramatically improve efficacy and compliance. Each platform technology is supported by in-depth technical know-how and a portfolio of both issued and pending patents, and each can be applied across a broad range of compounds and disease states.

MicroDose, a privately held company, has 55 employees and occupies 18,000 sq ft of office and laboratory space just North of Princeton, NJ. MicroDose has multi-product license agreements for its inhaler with Novartis and Merck among other collaborations.

### MicroDose Delivery Platforms



#### The MicroDose Dry Powder Inhaler

Through the innovative use of off-the-shelf, state-of-the-art electronics, MicroDose has created the premier next-generation Dry Powder Inhaler (DPI) for delivery of drugs to the lungs. Utilizing a high frequency piezo transducer, the MicroDose inhaler achieves: superior dose delivery efficiency that is flow rate, orientation, and coordination independent. All in a low-cost, reusable, multi-unit dose, pocket-sized device.



#### The MicroDose PolyCap™ System

In response to the growing need for a simple, effective, and low cost oral delivery system to deliver multiple medications in a capsule – MicroDose has created the PolyCap™ System, a proprietary approach that enables the rapid development of FDC therapies in a single dose, but separated by a physical barrier. Relying on the proven strengths of capsules and the advantages of a barrier system, it allows for more rapid development timelines, reduced risk, and lower regulatory requirements.



#### The MicroDose Needlefree System

Injection with a needle is still the only established route of administration for large molecules, but injections are disliked by patients and can be a safety hazard for healthcare professionals. In response, MicroDose is developing a revolutionary new needlefree system which will deliver the dose in micro-liter quantities in rapid pulses. This novel approach is capable of delivering large molecules, and uses “off-the-shelf” electronic piezo transducers in a revolutionary, programmable way that controls the delivery accurately and reproducibly.



MicroDoseTherapeutx

732.355.2100 main  
732.355.2101 fax

4262 US Route 1  
Monmouth Junction, NJ  
08852-1947  
[mdtx.com](http://mdtx.com)

**For Sales & Marketing**  
Scott Fleming  
Sr. Vice President  
Sales & Marketing  
732.355.2114  
[sfleming@mdtx.com](mailto:sfleming@mdtx.com)

**For Career Opportunities**  
Nancy Wolman  
Director  
Human Resources  
732.355.2130  
[nwolman@mdtx.com](mailto:nwolman@mdtx.com)

## In the MicroDose Pipeline

### Partnered Products

#### Merck

PRODUCT: Undisclosed inhalation product

DESCRIPTION: This product is being developed for pulmonary delivery for an undisclosed indication. The product entered Phase I in July 2008 and is currently under development in preparation for Phase 2 study.

#### Novartis

PRODUCT: Undisclosed inhalation product for respiratory disease

DESCRIPTION: This product development is for a NCE to treat respiratory disease and is in the pre-clinical stage.

#### Undisclosed partner 1

PRODUCT: Undisclosed inhalation product for respiratory disease

DESCRIPTION: This program is developing a preclinical NCE to treat respiratory disease.

#### Undisclosed partners 2 and 3

DESCRIPTION: Both programs are evaluating undisclosed NCEs to treat respiratory disease and are in research stage.

### Proprietary Products

#### MetPril

PRODUCT: MetPril™

DESCRIPTION: MetPril™ is a fixed-dose-combination therapy utilizing MicroDose's proprietary PolyCap™ capsule technology. The product is indicated for the co-morbid treatment of Type 2 diabetes and hypertension.

#### Atropine

PRODUCT: Inhalable dry powder atropine as organophosphate poisoning antidote

DESCRIPTION: Inhaled atropine sulphate is being developed as an antidote against nerve gas poisoning for the U.S. Department of Defense. The product is currently in Phase I.

### Joint Venture Products

#### QDose

PRODUCT: Inhaled insulin

DESCRIPTION: A dry powder insulin formulation for inhalation for the treatment of Type 1 and Type 2 diabetes mellitus. Product has completed two Phase 1 proof-of-concept studies. Program is currently on hold pending market review of inhaled insulin sales potential.

## Management Team

#### Anand V. Gumaste

President and Chief Executive Officer  
Chairman of the MicroDose Board

#### F. Scott Fleming

Senior Vice President, Sales & Marketing

#### David A. Byron

Vice President, Research & Development

#### Michael J. Martin

Vice President, Licensing & Business Development

#### John S. Krall III, CPA

Senior Director, Finance

#### Kent D. Mosier

Senior Director, Engineering

#### Robert O. Cook, PhD

Senior Director, Product Commercialization

#### Ronald W. Britt, PhD

Director, Quality Assurance

#### Eugene R. Reynolds, PhD

Director, Analytical Chemistry

#### Nancy L. Wolman

Director, Human Resources



MicroDoseTherapeutx

732.355.2100 main  
732.355.2101 fax

4262 US Route 1  
Monmouth Junction, NJ  
08852-1947  
mdtx.com